Alpine is a biotech stock that had an earnings report beating estimates two weeks ago. It
is now reaching for all-time highs. That said, it is burning cash just slowing down the burn.
Both revenue and earnings showed remarkable improvement as compared with the previous
quarter. The bullish momentum of price and volume is obvious on the weeky chart with
the...
In a strategic move set to shake up the biotech landscape, Vertex Pharmaceuticals ( NASDAQ:VRTX ) has announced its acquisition of Alpine Immune Sciences ( NASDAQ:ALPN ) in a blockbuster $4.9 billion deal. The news, which sent shockwaves through the market, made Alpine Immune Sciences ( NASDAQ:ALPN ) stock surge by 20.8% in Wednesday's Trading Session.
Alpine...
Similar to my recent SGMO idea, my view is that aVWAP support, 50% retracement and 50 day EMA support make a strong case that a relative low is in and higher prices are soon to come. For ALPN, the aVWAP cluster from recent significant lows/highs all cluster in a tight range in the mid 11s, which is right where the stock reversed. Likewise, if the stock goes below...
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101
Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in...
First off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, given the current Alpine price, analyst have been giving it a strong buy rating and it looks like it is having a retracement of around early 2020 price. I think a reasonable short target if it is truly going to rally could...
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The firm engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is...
Technically setting up for breakout.
200ma may be break.
Downtrend approaching.
RSI just crossed mid point.
MACD reversing off Zero line as Histogram ticks higher
Average analysts price target $11 ! Buy
Company profile
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The firm engages in the discovering of protein-based immunotherapies...
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is...
Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed...
